Andreas Damaske new General Manager of Intendis Dermatologie GmbH

 

• go to german version
• back to news overview

Berlin, March 16, 2006

The management of Intendis GmbH announced today that Mr. Andreas Damaske will become the new General Manager of Intendis Dermatologie GmbH with effect from May 1, 2006. Intendis Dermatologie GmbH is the German sales company of Intendis GmbH. Mr. Damaske will take over from Mr. Friedrich Gause, who has accepted a position at the Diagnostic Imaging unit of Schering AG.

”After so many years of working in Germany, Mr. Damaske knows the market extremely well. In addition he has gathered experience in many different areas – from sales to strategic marketing to structuring some of the Intendis subsidiaries. He is the ideal choice for this important position within the Intendis group,” emphasizes Prof. Dr. Wolfgang Kehr, President and CEO of Intendis GmbH.

Andreas Damaske started his career in 1986 when he trained as an industrial clerk at Schering AG. In the years that followed he held a number of sales and marketing positions within Schering and its subsidiaries, ranging from Key Account Manager to Head of the Customer Service Center of the Diagnostics business unit and Head of Sales Force for the Therapeutics segment at Jenapharm. In February 2005 Mr. Damaske assumed the function of Regional Business Manager Europe in Global Strategic Marketing and Sales at Intendis GmbH. In this role he was instrumental in setting up the subsidiaries in Portugal and Poland – for the latter he was a member of the Management Board.

Intendis is a fully integrated pharmaceutical company – dedicated to dermatology. Intendis is focused on the development, manufacturing and marketing of high quality, innovative topical and systemic therapies, targeted to treat skin disorders. The current product portfolio comprises treatments of eczema disorders including atopic dermatitis, as well as psoriasis, acne, rosacea and fungal skin infections (mycoses). Intendis markets a number of successful brands such as Advantan® and Nerisona® for the treatment of eczema, Travocort® (dermatomycoses), Skinoren® (acne), Finacea® (rosacea) and Psorcutan® and Psorcutan® Beta (psoriasis). The company’s objective is to become a leading partner in the field of dermatology. Intendis GmbH is a wholly-owned subsidiary of Schering AG, Germany.

This press release has been published by Corporate Communication of Intendis GmbH, Berlin, Germany.

Your contact at Corporate Communication:
Intendis GmbH	Sven Winkler +49 30 52 00 75 650 media@intendis.com

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Intendis’ plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Intendis GmbH undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

• Download, 77 KB